Trial Profile

A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Capecitabine (Primary) ; Inavolisib (Primary) ; Talazoparib (Primary) ; Pembrolizumab
Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms PERSEVERE

Most Recent Events

31 May 2025 Status changed from active, no longer recruiting to discontinued as per funder decision
26 Sep 2024 Status changed from recruiting to active, no longer recruiting.
11 Oct 2022 Planned End Date changed from 1 Jan 2029 to 31 Jan 2034.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com